Molecular genetic methods for quality control of inactivated vaccines using a Chikungunya virus model: vaccine strain identification and completeness of virus inactivation
INTRODUCTION. The completeness of virus inactivation and the identity of the vaccine strain are essential parameters for the safety and quality of inactivated virus vaccines, which should be controlled during vaccine development and production. Currently, the most promising quality control methods f...
Gespeichert in:
| Veröffentlicht in: | Biopreparaty Jg. 24; H. 3; S. 279 - 293 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Magazine Article |
| Sprache: | Englisch Russisch |
| Veröffentlicht: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products
03.10.2024
|
| Schlagworte: | |
| ISSN: | 2221-996X, 2619-1156 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | INTRODUCTION.
The completeness of virus inactivation and the identity of the vaccine strain are essential parameters for the safety and quality of inactivated virus vaccines, which should be controlled during vaccine development and production. Currently, the most promising quality control methods for inactivated virus vaccines are molecular genetic methods, which provide rapid results with high sensitivity and specificity.
AIM
. The aim of this study was the development of a real-time quantitative polymerase chain reaction (qPCR) method and an integrated cell culture real-time quantitative polymerase chain reaction (ICC-qPCR) method to assess the completeness of virus inactivation, as well as a reverse-transcription polymerase chain reaction assay coupled with restriction fragment length polymorphism analysis (RT-PCR-RFLP) to confirm the identity of the vaccine virus strain.
MATERIALS AND METHODS
. This study used RNA of CHIKV genotypes (three strains of each of the four CHIKV genotypes, including Asian, West African (WAf), and East/Central/South African (ECSA) genotypes, and the Indian Ocean Lineage of the ECSA genotype (ECSA-IOL), which were identified by sequencing prior to analysis). Additionally, the study used the Nika21 CHIKV strain (ECSA genotype), the Nika21 CHIKV strain inactivated with β-propiolactone, and the Nika21 CHIKV strain antigen adsorbed on aluminium hydroxide. The methods used included real-time qPCR, RT-PCR-RFLP, and virus neutralisation.
RESULTS.
The study identified a 218 bp fragment of the nsP1 gene (positions 789 to 1006) with restriction endonuclease recognition sites. These sites were present or absent in combinations specific to each of the four CHIKV genotypes. The authors selected primers for amplification of the specified gene region and tested the conditions for real-time qPCR and RT-PCR-RFLP. The study demonstrated the possibility of using the ICC-qPCR method to confirm the completeness of virus inactivation and the RT-PCR-RFLP method to identify the vaccine strain.
CONCLUSIONS
. The study showed the advantages of using the ICC-qPCR method to confirm the completeness of antigen inactivation and the RT-PCR-RFLP method to identify the vaccine strain. These methods are more sensitive and faster than traditional culture methods. ICC-qPCR and RT-PCR-RFLP can be used at any stage of the production process for inactivated vaccines. |
|---|---|
| AbstractList | INTRODUCTION.
The completeness of virus inactivation and the identity of the vaccine strain are essential parameters for the safety and quality of inactivated virus vaccines, which should be controlled during vaccine development and production. Currently, the most promising quality control methods for inactivated virus vaccines are molecular genetic methods, which provide rapid results with high sensitivity and specificity.
AIM
. The aim of this study was the development of a real-time quantitative polymerase chain reaction (qPCR) method and an integrated cell culture real-time quantitative polymerase chain reaction (ICC-qPCR) method to assess the completeness of virus inactivation, as well as a reverse-transcription polymerase chain reaction assay coupled with restriction fragment length polymorphism analysis (RT-PCR-RFLP) to confirm the identity of the vaccine virus strain.
MATERIALS AND METHODS
. This study used RNA of CHIKV genotypes (three strains of each of the four CHIKV genotypes, including Asian, West African (WAf), and East/Central/South African (ECSA) genotypes, and the Indian Ocean Lineage of the ECSA genotype (ECSA-IOL), which were identified by sequencing prior to analysis). Additionally, the study used the Nika21 CHIKV strain (ECSA genotype), the Nika21 CHIKV strain inactivated with β-propiolactone, and the Nika21 CHIKV strain antigen adsorbed on aluminium hydroxide. The methods used included real-time qPCR, RT-PCR-RFLP, and virus neutralisation.
RESULTS.
The study identified a 218 bp fragment of the nsP1 gene (positions 789 to 1006) with restriction endonuclease recognition sites. These sites were present or absent in combinations specific to each of the four CHIKV genotypes. The authors selected primers for amplification of the specified gene region and tested the conditions for real-time qPCR and RT-PCR-RFLP. The study demonstrated the possibility of using the ICC-qPCR method to confirm the completeness of virus inactivation and the RT-PCR-RFLP method to identify the vaccine strain.
CONCLUSIONS
. The study showed the advantages of using the ICC-qPCR method to confirm the completeness of antigen inactivation and the RT-PCR-RFLP method to identify the vaccine strain. These methods are more sensitive and faster than traditional culture methods. ICC-qPCR and RT-PCR-RFLP can be used at any stage of the production process for inactivated vaccines. INTRODUCTION. The completeness of virus inactivation and the identity of the vaccine strain are essential parameters for the safety and quality of inactivated virus vaccines, which should be controlled during vaccine development and production. Currently, the most promising quality control methods for inactivated virus vaccines are molecular genetic methods, which provide rapid results with high sensitivity and specificity.AIM. The aim of this study was the development of a real-time quantitative polymerase chain reaction (qPCR) method and an integrated cell culture real-time quantitative polymerase chain reaction (ICC-qPCR) method to assess the completeness of virus inactivation, as well as a reverse-transcription polymerase chain reaction assay coupled with restriction fragment length polymorphism analysis (RT-PCR-RFLP) to confirm the identity of the vaccine virus strain.MATERIALS AND METHODS. This study used RNA of CHIKV genotypes (three strains of each of the four CHIKV genotypes, including Asian, West African (WAf), and East/Central/South African (ECSA) genotypes, and the Indian Ocean Lineage of the ECSA genotype (ECSA-IOL), which were identified by sequencing prior to analysis). Additionally, the study used the Nika21 CHIKV strain (ECSA genotype), the Nika21 CHIKV strain inactivated with β-propiolactone, and the Nika21 CHIKV strain antigen adsorbed on aluminium hydroxide. The methods used included real-time qPCR, RT-PCR-RFLP, and virus neutralisation.RESULTS. The study identified a 218 bp fragment of the nsP1 gene (positions 789 to 1006) with restriction endonuclease recognition sites. These sites were present or absent in combinations specific to each of the four CHIKV genotypes. The authors selected primers for amplification of the specified gene region and tested the conditions for real-time qPCR and RT-PCR-RFLP. The study demonstrated the possibility of using the ICC-qPCR method to confirm the completeness of virus inactivation and the RT-PCR-RFLP method to identify the vaccine strain.CONCLUSIONS. The study showed the advantages of using the ICC-qPCR method to confirm the completeness of antigen inactivation and the RT-PCR-RFLP method to identify the vaccine strain. These methods are more sensitive and faster than traditional culture methods. ICC-qPCR and RT-PCR-RFLP can be used at any stage of the production process for inactivated vaccines. |
| Author | Oksanich, A. S. Kaa, K. V. Samartseva, T. G. Laputina, A. G. Netesova, N. A. Otrashevskaia, E. V. Ignatyev, G. M. Krasko, A. G. |
| Author_xml | – sequence: 1 givenname: A. S. orcidid: 0000-0002-8600-7347 surname: Oksanich fullname: Oksanich, A. S. organization: I. Mechnikov Research Institute of Vaccines and Sera – sequence: 2 givenname: T. G. orcidid: 0000-0003-3264-6722 surname: Samartseva fullname: Samartseva, T. G. organization: I. Mechnikov Research Institute of Vaccines and Sera – sequence: 3 givenname: K. V. orcidid: 0000-0002-8446-1853 surname: Kaa fullname: Kaa, K. V. organization: Centre for Strategic Planning and Management of Biomedical Health Risks – sequence: 4 givenname: E. V. orcidid: 0000-0002-2491-4072 surname: Otrashevskaia fullname: Otrashevskaia, E. V. organization: I. Mechnikov Research Institute of Vaccines and Sera – sequence: 5 givenname: A. G. orcidid: 0000-0002-2765-3525 surname: Krasko fullname: Krasko, A. G. organization: Republican Research and Practical Center for Epidemiology and Microbiology – sequence: 6 givenname: A. G. orcidid: 0009-0006-7527-6951 surname: Laputina fullname: Laputina, A. G. organization: I. Mechnikov Research Institute of Vaccines and Sera – sequence: 7 givenname: N. A. orcidid: 0000-0002-9896-5403 surname: Netesova fullname: Netesova, N. A. organization: State Research Center of Virology and Biotechnology “Vector” – sequence: 8 givenname: G. M. orcidid: 0000-0002-9731-3681 surname: Ignatyev fullname: Ignatyev, G. M. organization: I. Mechnikov Research Institute of Vaccines and Sera; Saint Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations |
| BookMark | eNo9kd9uFCEUxiemJtbad-DCW5Q_M8NgvDEbrU1qelMT78gZOGyps1CB2WSfyZeU7domJ4FwPr6Pw-9tdxZTxK57z9kHySY9fBRCcKr1-IsKJnraSlKhNBVavurOxcg15XwYz9r-WfmmuyzlgTEmJjWOWp93f3-kBe26QCZbjFiDJTus98kV4lMmf1ZYQj0Qm2LNaSHJkxDB1rCHio7swdoQsZC1hLglQDb34fcat2s8ANmHvBaySw6XT89KUmqGEElwGGvwwUINKRKIrkXsHhes7RGlHHNO11_Smuxd99rDUvDy_3rR_fz29W7znd7cXl1vvtxQy5WUVHLu5QTz0KaeEL1TsxCo5lnhgCCAtbabNI5OMQcSJzeInjmvHJM9n5S86K5Pvi7Bg3nMYQf5YBIE83SQ8tZAbj-1oMEevGSsB9VDz8WseztLNzM1DxOT1javzycvm1MpGf2LH2fmiaM50jFHOubI0bSSpnE0jaP8B2V5mPI |
| Cites_doi | 10.36233/0372-9311-2020-97-2-182-189 10.1016/j.scitotenv.2018.04.223 10.1080/10934529.2015.1019795 10.3390/pathogens10050626 10.1128/JCM.38.9.3156-3160.2000 10.1016/j.jviromet.2018.05.008 10.1128/AEM.66.5.2267-2268.2000 10.1016/j.vaccine.2012.07.072 10.30895/2221-996X-2023-23-1-111-120 10.30895/2221-996X-2022-22-4-405-413 10.1385/1-59259-766-1:069 10.1186/1743-422X-6-149 10.36233/0372-9311-2019-4-38-46 10.1016/j.vaccine.2009.07.095 10.3389/fimmu.2020.00592 10.36233/0372-9311-196 10.1016/j.mimet.2010.04.003 10.1016/j.jviromet.2019.04.025 10.1016/j.vaccine.2009.02.062 10.30895/2221-996X-2020-20-2-107-115 10.36233/0372-9311-159 10.3382/ps.2013-03134 10.1016/j.jhin.2022.04.008 10.30895/2221-996X-2023-23-1-42-64 10.1371/journal.pntd.0008142 10.1007/82_2018_146 10.1016/j.jviromet.2006.10.001 |
| ContentType | Magazine Article |
| DBID | AAYXX CITATION DOA |
| DOI | 10.30895/2221-996X-2024-24-3-279-293 |
| DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2619-1156 |
| EndPage | 293 |
| ExternalDocumentID | oai_doaj_org_article_e4af3004a74a412b94cb3db07b5803cc 10_30895_2221_996X_2024_24_3_279_293 |
| GroupedDBID | AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ |
| ID | FETCH-LOGICAL-c1733-311f38ab52218eefd7b22e7bb7e5ea2a01f3d89e6d70da3e8d5240df7d0341873 |
| IEDL.DBID | DOA |
| ISSN | 2221-996X |
| IngestDate | Fri Oct 03 12:50:52 EDT 2025 Sat Nov 29 05:35:10 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English Russian |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1733-311f38ab52218eefd7b22e7bb7e5ea2a01f3d89e6d70da3e8d5240df7d0341873 |
| ORCID | 0000-0002-8446-1853 0000-0002-9731-3681 0000-0002-9896-5403 0000-0003-3264-6722 0000-0002-8600-7347 0000-0002-2491-4072 0000-0002-2765-3525 0009-0006-7527-6951 |
| OpenAccessLink | https://doaj.org/article/e4af3004a74a412b94cb3db07b5803cc |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e4af3004a74a412b94cb3db07b5803cc crossref_primary_10_30895_2221_996X_2024_24_3_279_293 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-10-03 |
| PublicationDateYYYYMMDD | 2024-10-03 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationTitle | Biopreparaty |
| PublicationYear | 2024 |
| Publisher | Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products |
| Publisher_xml | – name: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products |
| References | ref13 ref12 ref15 ref14 ref31 ref30 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – ident: ref13 doi: 10.36233/0372-9311-2020-97-2-182-189 – ident: ref3 – ident: ref10 doi: 10.1016/j.scitotenv.2018.04.223 – ident: ref28 doi: 10.1080/10934529.2015.1019795 – ident: ref4 doi: 10.3390/pathogens10050626 – ident: ref22 – ident: ref14 doi: 10.1128/JCM.38.9.3156-3160.2000 – ident: ref27 doi: 10.1016/j.jviromet.2018.05.008 – ident: ref11 doi: 10.1128/AEM.66.5.2267-2268.2000 – ident: ref20 doi: 10.1016/j.vaccine.2012.07.072 – ident: ref23 doi: 10.30895/2221-996X-2023-23-1-111-120 – ident: ref25 doi: 10.30895/2221-996X-2022-22-4-405-413 – ident: ref15 – ident: ref30 – ident: ref7 doi: 10.1385/1-59259-766-1:069 – ident: ref9 doi: 10.1186/1743-422X-6-149 – ident: ref12 doi: 10.36233/0372-9311-2019-4-38-46 – ident: ref29 doi: 10.1016/j.vaccine.2009.07.095 – ident: ref18 doi: 10.3389/fimmu.2020.00592 – ident: ref21 doi: 10.36233/0372-9311-196 – ident: ref5 doi: 10.1016/j.mimet.2010.04.003 – ident: ref1 doi: 10.1016/j.jviromet.2019.04.025 – ident: ref19 doi: 10.1016/j.vaccine.2009.02.062 – ident: ref16 doi: 10.30895/2221-996X-2020-20-2-107-115 – ident: ref24 doi: 10.36233/0372-9311-159 – ident: ref31 doi: 10.3382/ps.2013-03134 – ident: ref8 doi: 10.1016/j.jhin.2022.04.008 – ident: ref17 doi: 10.30895/2221-996X-2023-23-1-42-64 – ident: ref2 doi: 10.1371/journal.pntd.0008142 – ident: ref26 doi: 10.1007/82_2018_146 – ident: ref6 doi: 10.1016/j.jviromet.2006.10.001 |
| SSID | ssj0002876699 |
| Score | 1.3648255 |
| Snippet | INTRODUCTION.
The completeness of virus inactivation and the identity of the vaccine strain are essential parameters for the safety and quality of inactivated... INTRODUCTION. The completeness of virus inactivation and the identity of the vaccine strain are essential parameters for the safety and quality of inactivated... |
| SourceID | doaj crossref |
| SourceType | Open Website Index Database |
| StartPage | 279 |
| SubjectTerms | chikungunya virus integrated cell culture quantitative pcr restriction fragment length polymorphism method reverse transcription polymerase chain reaction |
| Title | Molecular genetic methods for quality control of inactivated vaccines using a Chikungunya virus model: vaccine strain identification and completeness of virus inactivation |
| URI | https://doaj.org/article/e4af3004a74a412b94cb3db07b5803cc |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYllNJTXylJX8wh5BQRW4-V3FsbGnpp2EMCexOSJSVOwSnr7ML-pv7Jzsi7m80pl4JOsmQbf4NmZM18H2NHQuqWeMq51MFwJVPiXgXPZaZjmGxDJUIRmzAXF3Y2a6Y7Ul-UEzbSA48f7jQpn4kVyhvlVS1Co9ogY6hM0LaSbUurb2Wanc3UbfllZCaTIh6J_q_mGNTPXrAj2qJWttGn2040EqE4NsmFabho5CP_tEPjX_zN-Wv2akP8DN_GN3zDns0Xb9nxdKSaXp3A5UPl1HACxzB9IKFevWN_f210bwFNhCoVYRSLHgDDVBhrKVewzlSHuwxdTzUOS4w9Iyx9SwfuA1Ba_DV4OLvpfuOysOhXHpbdfDFAkdD5uhkJQ9GagC6us48K4OD7CCVpnUJzXFPpOeP07dNw2D67Ov9xefaTr4UZeFsbSfV4dZbWB4zdaptSjiYIkUwIJunkha_wcrRNmkRTRS-TjRoDh5hNrNBpWiPfs73-rk8HDEQUIsScdc5RaRGbKL1udahVQkcp6kOmN3C4PyP_hsN9S4HREYyOYHQEo8MmHcLoEMZD9p2w284hFu3Sgbbl1rblnrKtD__jJh_Zy2JklHQgP7G9-_kifWbP2-V9N8y_FLP9B2u48xc |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+genetic+methods+for+quality+control+of+inactivated+vaccines+using+a+Chikungunya+virus+model%3A+vaccine+strain+identification+and+completeness+of+virus+inactivation&rft.jtitle=Biopreparaty&rft.au=A.+S.+Oksanich&rft.au=T.+G.+Samartseva&rft.au=K.+V.+Kaa&rft.au=E.+V.+Otrashevskaia&rft.date=2024-10-03&rft.pub=Ministry+of+Health+of+the+Russian+Federation.+Federal+State+Budgetary+Institution+%C2%ABScientific+Centre+for+Expert+Evaluation+of+Medicinal+Products&rft.issn=2221-996X&rft.eissn=2619-1156&rft.volume=24&rft.issue=3&rft.spage=279&rft.epage=293&rft_id=info:doi/10.30895%2F2221-996X-2024-24-3-279-293&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e4af3004a74a412b94cb3db07b5803cc |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2221-996X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2221-996X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2221-996X&client=summon |